A Phase II open-label, Multicenter study of Apalutamide, Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate-resistant prostate cancer
Clinical Trial Grant
Awarded By
Janssen Pharmaceutica, Inc.
Start Date
May 11, 2017
End Date
April 30, 2026
Awarded By
Janssen Pharmaceutica, Inc.
Start Date
May 11, 2017
End Date
April 30, 2026